Listed below are common services we provide. Your referring physician may have mentioned one of these as a next step for you. Don’t be intimidated by the medical jargon—we will answer any questions you may have during your appointment with us to ensure your confidence and comfort.
- Fluorescein Angiography: This procedure is a photographic study of the retinal blood vessels. Dye injected into a vein in your arm travels to blood vessels in the eye, and then we use a special camera to photograph those vessels.
- Indocyanine Green Angiography (ICG): Similar to Fluorescein Angiography, this procedure can give more information about certain diseases.
- Fundus Photography: This test uses color photography and a microscope to reveal and document retinal disease.
- Optical Coherence Tomography (OCT): This imaging procedure provides cross sectional images of the retina layer and is used in the diagnosis of retinal diseases.
- Ultrasonography: This technique produces images of the inner structures of the eye by using sound waves.
- Repair and Reconstruction of Ocular Injuries: Numerous surgical procedures can repair injuries to the eye and preserve vision, even in cases of severe eye trauma.
- Intravitreal Injections: These office-based procedures provide treatment for macular degeneration and other vascular abnormalities of the eye.
- Laser Photocoagulation: A laser is a highly focused beam of light that is absorbed by tissue; laser photocoagulation is used in many delicate forms of surgery.
- Photodynamic Therapy/Ocular Photodynamic Therapy: This advanced treatment for macular degeneration and other macular diseases uses a laser and laser-activated medication.
- Vitrectomy: This microscopic technique repairs the interior of the eye.
- Retinal Detachment Repair: This repair reattaches the retina to its normal position within the eye.
- Macular Hole Repair: This vitrectomy procedure repairs a common vision threatening condition.
- Cutting Edge Tests and Treatments: Retina Consultants periodically offers participation in clinical trials for late-stage testing of the latest in eye health procedures. Learn More Here.
When possible, we offer our patients the option to participate in clinical trials. Clinical trials allow cutting edge treatment options to be tested by the people they were designed to help.
Protocol UBX1325-02: July 2021-present:
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
Sponsor: UNITY Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT04857996
Protocol ADX-2191-PVR-001: June 2021-present:
A Multicenter, Randomized, Controlled, Prospective, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 versus Standard-of-Care for the Prevention of Proliferative Vitreoretinopathy
Sponsor: Aldeyra Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04136366
Protocol OPT-302-1005: April 2021 – Present:
A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
ClinicalTrials.gov Identifier: NCT04757636
Protocol ISIS 696844-CS5: March 2021 – Present:
A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Ionis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03815825
Protocol AU-011-202: August 2020 – Present:
A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma.
Sponsor: Aura Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT04417530
Protocol AU-001-101: February 2019 – Present:
A Phase 1b/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma. Closed to Enrollment.
Sponsor: Aura Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT03052127
Protocol GR40398: RHINE for Diabetic Macular Edema Study: February 2019 – Present:
A Phase III, Multicenter, Randomized, Double- Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients with Diabetic Macular Edema
Sponsor: F. Hoffman-La Roche Ltd
ClinicalTrials.gov Identifier: NCT03622593